Shattuck Labs (NASDAQ:STTK) Given New $7.00 Price Target at Citigroup

Shattuck Labs (NASDAQ:STTK) had its price target boosted by Citigroup from $4.00 to $7.00 in a report published on Friday,Benzinga reports. They currently have a neutral rating on the stock.

STTK has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a research note on Monday, December 1st. Wedbush upped their target price on shares of Shattuck Labs from $4.00 to $8.00 and gave the company an “outperform” rating in a report on Friday, March 6th. TD Cowen reiterated a “buy” rating on shares of Shattuck Labs in a research note on Friday, March 6th. Finally, Piper Sandler began coverage on Shattuck Labs in a report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price target on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.50.

Shattuck Labs Trading Down 2.3%

Shares of NASDAQ STTK opened at $5.99 on Friday. The stock has a market cap of $428.64 million, a P/E ratio of -7.78 and a beta of 1.55. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $6.25. The stock has a 50 day moving average of $4.41 and a two-hundred day moving average of $3.00.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to analysts’ expectations of $0.17 million. As a group, research analysts predict that Shattuck Labs will post -1.48 earnings per share for the current year.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors have recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. purchased a new position in Shattuck Labs during the 4th quarter worth $4,945,000. Invesco Ltd. purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at about $103,000. EP Wealth Advisors LLC acquired a new position in shares of Shattuck Labs during the fourth quarter worth about $150,000. Sphera Funds Management LTD. purchased a new position in Shattuck Labs during the fourth quarter worth about $713,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Shattuck Labs during the fourth quarter worth about $7,031,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.